

Eyegate Pharmaceuticals, Inc.

Providing innovative products that enhance drug efficacy and patient compliance to improve vision

> Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-197725 January 16, 2015



Some of the matters discussed in this presentation contain forward-looking statements that involve significant risks and uncertainties, including statements relating to the prospects for the Company's lead product EGP-437, for the timing and outcome of the Company's clinical trials, the potential approval to market EGP-437, and the Company's capital needs. Actual events could differ materially from those projected in this presentation and the Company cautions investors not to rely on the forward-looking statements contained in, or made in connection with, the presentation.

Among other things, the Company's clinical trials may be delayed or may eventually be unsuccessful. The Company may consume more cash than it currently anticipates and faster than projected. Competitive products may reduce or eliminate the commercial opportunities of the Company's product candidates. If the FDA or foreign regulatory agencies determine that the Company's product candidates do not meet safety or efficacy endpoints in clinical evaluations, they will not receive regulatory approval and the Company will not be able to market them. Operating expense and cash flow projections involve a high degree of uncertainty, including variances in future spending rate due to changes in corporate priorities, the timing and outcomes of clinical trials, regulatory and developments and the impact on expenditures and available capital from licensing and strategic collaboration opportunities. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly alter, delay, scale back or discontinue operations.

Additional risks and uncertainties relating to the Company and its business can be found in the "Risk Factors" section of the Company's Registration Statement on Form S-1, as amended to date. The Company undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or changes in the Company's expectations, except as required by applicable law.



- This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all of the information that you should consider before investing in our company.
- We have filed a registration statement (including a prospectus) with the United States Securities and Exchange Commission (SEC) for the offering to which this presentation relates. The registration statement has not yet become effective. Before you invest, you should read the prospectus in the registration statement (including the risk factors described therein) and other documents we have filed with the SEC for more complete information about us and the offering. You may get these documents, including the preliminary prospectus dated December 24, 2014, for free by visiting EDGAR on the SEC website at http://sec.gov. The preliminary prospectus, dated December 24, 2014, is available on the SEC website at http://www.sec.gov/Archives/edgar/data/1372514/000114420414075901/v395878 s1a.htm
- Alternatively, we or any underwriter participating in the offering will arrange to send you the prospectus if you contact Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone 212-813-1010, email: prospectus@aegiscap.com



Issuer	Eyegate Pharmaceuticals, Inc.			
Exchange / Ticker	NASDAQ Capital Market / EYEG			
Offering Size	1,428,572 shares (100% primary)			
Over-Allotment	15% or 214,286 shares (100% primary)			
Price Range	\$6.00 - \$8.00			
Use of Proceeds	Continue clinical development of lead program for anterior uveitis indication and conduct proof-of-concept macular edema trial. Working capital and other general purposes.			
Joint Bookrunning Managers	Aegis Capital Corp. and Chardan Capital Markets, LLC			

Management Team



Stephen From, President & CEO

- With EyeGate since October 2005
- Former CFO, Centelion SAS (Aventis subsidiary)
- Healthcare investment Banker
- Qualified Chartered Accountant (PwC)

Michael Manzo, VP Engineering

- With EyeGate since October 2006
- Over 30 years of experience in product development and manufacturing in the medical device industry
- Former President and COO, Jenline Industries (now part of Helix Medical)
- Senior Marketing Engineer, ONUX Medical

Lisa Brandano, Director, Clinical Operations

- Former Assistant Managing Director of the Boston office and Director, Clinical Trial Operations, CATO Research
- Beth Israel Deaconess Medical Center, Boston

Michael Patane Ph.D., CSO (Consultant)

- Exec. Director, Global Discovery Chemistry, Novartis, responsible for infectious diseases and ophthalmology
- Director, Medicinal Discovery, Millennium Pharma

Michael Raizman M.D., Consultant

- Specialist in Laser Vision Correction and Treatment of the Cornea, Ophthalmic Consultants of Boston
- Associate Professor of Ophthalmology, Tufts University

Board of Directors with Ophthalmic Experience and Medical Advisors



Selected Board Members

Paul Chaney (Chairman)

- President and CEO of PanOptica, Inc.
- 25 years experience in pharmaceutical industry including several VP positions at Pharmacia

Morton Goldberg M.D.*

- Joseph E. Green Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine
- Former Director and William Holland Wilmer Professor of Ophthalmology, Wilmer Eye Institute
- Praveen Tyle PhD.
 - President and CEO of Osmotica Pharma.
 - SVP and Global Head Business Development & Licensing for Novartis Consumer Health OTC
 - Former VP of R&D and Chief Scientific Officer for Bausch & Lomb

Selected Medical Advisors

Victor Perez M.D.

- Director of the Ocular Surface Center and the Walter G. Ross Distinguished Chair in Ophthalmic Research Programs at the Bascom Palmer Eye Institute
- Professor of Ophthalmology, Microbiology and Immunology, University of Miami Miller School of Medicine ,

John Sheppard M.D.

- President, Virginia Eye Consultants: Research, Education & Clinical Excellence
- Professor of Ophthalmology, Microbiology & Molecular Biology, Ophthalmology Residency Research Director, Clinical Director, Thomas R. Lee Center for Ocular Pharmacology, Eastern Virginia Medical School
- Stephen Foster M.D.
 - Founder and Director of the Massachusetts Eye Research and Surgery Institute (MERSI)
 - Author of over 500 published books and papers and has won numerous awards including The International Ocular Inflammation Society Award and The American Academy of Ophthalmology Senior Honor Award

cipation by Board Member does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System

Company Overview



- Late-stage specialty pharmaceutical and drug delivery company targeting highly prevalent ocular indications
 - Lead investors include Ventech, IPSA, Natixis
- Lead product candidate, EGP-437 for anterior uveitis, matched response rate for standard of care in non-inferiority trial
 - 505(b)(2) NDA filing scheduled for end of year 2016
 - EGP-437 being evaluated for back-of-eye disease, like macular edema
- EyeGate II® Delivery System: Proprietary, non-invasive delivery platform; >1,700 treatments performed to-date
 - System is approved through a 510(k) filing at time of drug NDA submission
 - Easy to use; can be done by ophthalmologist or optometrist in <5 minutes
 - · Delivers small and large molecules to anterior or posterior of eye
 - Significant patient and clinician advantages over drops or ocular injections
 - Safer, lower-risk alternative to intravitreal injection

Investment Highlights



7

- Late-stage lead asset with clear path to commercialization
 - EGP-437 completed first Phase 3 trial in anterior uveitis, and one pivotal trial left to complete, NDA submission expected by end of year 2016
 - EGP-437 will be developed for additional indications like macular edema a back-of-the-eye disease
- EyeGate[®] II Delivery System a potential paradigm-shift in ophthalmic drug administration
 - Treatment can be performed by range of eye care professionals (injectables must be administered by an experienced ophthalmologist)
 - Long-lasting, professionally delivered treatment eliminates compliance risk of patient-administered drops
- Robust US and international patent portfolio
 - Protection from 2018 through 2029^{*}

Granted patent protection until 2024, applications if granted extend this to 2029




Unique Ophthalmic Delivery Platform





9


Anterior Segment of the Eye



Primary mode of delivery is eye drops

- Problem: protective layer and biological functions limit penetration of drug into tissues
- Frequent instillations required: up to 16 per day
- Extremely heavy burden on patient resulting in noncompliance
- · Can result in sight-threatening complications


Posterior Segment of the Eye



- Primary mode of delivery is via intravitreal injection
- Safety concerns with potential for collateral damage
- Injections as frequent as monthly
- Must be completed by experienced ophthalmologist
- Excessive travel and companion required results in noncompliance
- · Can result in sight-threatening complications

EyeGate has the only Non-Invasive Solution






EyeGate Platform: A Non-Invasive Method

of Propelling Charged Active Compounds Into Ocular Tissues




Iontophoresis

- Small electrical current (constant); Current has same charge as active substance (drug)
- Electrode creates repulsive electromotive forces (electrorepulsion)
- Drug migrates toward return electrode
- Drug delivered in high local concentration with minimized systemic absorption
- Drug mobility is a function of molecular weight, solubility, and charge
- · Single system can deliver multiple drugs to treat multiple indications
- Iontophoretic dose (mA-min) = Current (mA) x Application time (minutes)
- Software-regulated current and duration ensures proper dosing of compatible compounds



EyeGate® II Delivery System Substantial Benefits for Clinicians and Patients







Program	Indication	Current Status	Use of Proceeds Milestones		
	Anterior Uveitis	Phase 1-2 dose ranging trial completed First non-inferiority trial completed	• Initiate Phase 3 pivotal trial		
EGP-437	Macular Edema		 Initiate and complete back-of-the-eye dose curve trial Initiate and complete Phase 2 proof of concept trial for macular edema 		
	Dry Eye	• Two trials completed (Phase 2 & Phase 3) (Stress Environment - placebo controlled)	• No further trials are anticipated with use of proceeds		
	Cataract Surgery	Phase 2 proof of concept trial completed (prophylactic - placebo controlled)			




EGP-437 Anti-Inflammatory


(corticosteroid - dexamethasone phosphate)



Uveitis Overview

- Inflammation of the uveal tract may be idiopathic, associated with systemic diseases or result from a variety of infectious agents
- An annual estimated 17.6% of active uveitis patients experience transient or permanent loss of vision. Uveitis is responsible for more than 2.8% of blindness in the U.S.
- Non-infectious anterior uveitis is a debilitating form of inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body and is the most common form of uveitis
- Incidence in the U.S. ranges from approximately 26.6 102 per 100,000 adults annually
- Chronic or recurrent, anterior uveitis and non-compliance of treatment may lead to complications such as posterior subcapsular cataract, glaucoma and macular edema






Non-compliance leads to sight-threatening complications



Standard of care to treat anterior uveitis is patient administered corticosteroid eye drops

- Topical corticosteroids suffer from a number of drawbacks including low ocular bioavailability, rapid clearance and steroid-related side effects, including elevated intraocular pressure, or IOP
- At minimum, patients are required to give themselves 154 treatments of the standard of care
- · Given heavy burden, patient non-compliance is prevalent and is the main cause of treatment failure
- Alternative is more aggressive steroid therapy, such as ocular and intravenous injections, which is often
 associated with steroid-related adverse effects such as elevated IOP and cataract formation





Anterior Uveitis Episode 1994 OS OD 20/80 20/20 "low grade chronic inflammation Same Patient 10 Years Later (2004): Poor Anti-Inflammatory Therapeutics OS OD No Light Perception 20/400 "Blind Legally Blind 17



Severity of Uveitis: SUN Working Group

Debilitating form of intraocular inflammation of the anterior portion of the uvea	Grade	Cells
Confirmation and severity of disease is determined by the number of white blood	0	< 1
cells in the anterior chamber of the eye (Slit-lamp is used)	0.5	1 to 5
 The Standardization of Uveitis Nomenclature (SUN) working group of 2004 	1.0	6 to 15
agreed that inactive disease (cell count of zero) is the goal of therapy	2.0	16 to 25
The SUN group created a grading scheme for determining degree of inflammation	3.0	26 to 50
Outlined an initial main and a self to be an demined to support the	4.0	> 50

Subjects required minimum 11 cells to be randomized to our study


Non-Infectious Anterior Segment Uveitis (>11 cells) non-inferiority Trial

- Primary objective: evaluate whether EGP-437 using the EyeGate® II Drug Delivery System (EGDS) is non-inferior to topical ophthalmic prednisolone acetate ophthalmic suspension (1%) (positive control) in patients with non-infectious anterior segment uveitis
- Primary End Point (PEP): Total cell clearing at Day 14
 - Patients exhibit a large number of white blood cells in the anterior chamber of the eye
 - In order to count these cells in the anterior chamber, the physician uses a slit lamp, focusing a thin sheet of light into the eye. The treatment objective is to eliminate the inflammation of the uvea which can be confirmed by an anterior chamber cell count of zero

Initial Phase 3 Non-Inferiority Anterior Uveitis Trial Trial Design and High-Level Results



Trial Design




High-Level Results

- Successfully demonstrated same response rate when comparing EGP-437 to standard of care (prednisolone acetate 1%) in Phase 3 trial of 193 patients with anterior uveitis
- Lower incidence of increased intraocular pressure (IOP) with EGP-437 treatment




Percent of subjects with cell count of 0 at each visit*



Safety







Just outside non-inferiority margin

rimary Endpoint: AC Cell Count = 0 t Day 14	ITT* (N = 193)			
	EGP-437	PA 1%		
Subjects with Day 14 AC Cell Count = 0	32	32		
Total Number of Subjects	96	97		
Proportion	33.3%	33.0%		
Difference (%) (95% Cl)	0. (-12.94%,			


 Proportion of subjects randomized with fewer than 25 cells (least severe population) was significantly higher in the control arm at baseline. Important as response rate similar for both arms in this population (43.2% vs 41.4% for EGP-437 vs PA 1% respectively).

		EGP	-437	7 PA 1%		PEP	
	Enrolled	No.	%	No.	%	No.	%
11 to 25 cells	102	44	43.1%	58	56.9%	43	42.2%
> 25 cells	91	52	57.1%	39	42.9%	21	23.1%
	193	96	49.7%	97	50.3%	64	33.2%

* ITT = intent to treat or full population,



- EGP-437 has demonstrated equivalent response rates for SUN grades 1.0, 2.0 and 3.0 and has demonstrated much better results (29% better) for the more severe 4.0 grade.
- Combining SUN grades 3.0 and 4.0 results in 25.0% and 20.5% response rates for EGP-437 and PA 1% respectively.




Additional Phase 3 Pivotal Trial Modified Design




Modified design provides stronger powering for non-inferiority PEP* and ability to show SUPERIORITY for more severe** population whilst maintaining similar trial size

- Modification: Three (3) treatments of EGP-437 prior to Day 14 primary endpoint (PEP)
- N: 250 subjects (90% powering for non-inferiority PEP with whole population)
- Randomization will be stratified by the baseline severity of the condition, according to the SUN scale, to
 ensure a more even distribution between the two treatment groups
- Subjects randomized to SUN groups 1.0 and 2.0 will be limited to approximately 120 subjects
- Primary endpoint is non-inferiority for whole population
- Secondary endpoint for superiority of the more severe group (> 26 cells)
- Provides ability to put both claims on the label

* PEP = Primary Endpoint ** SUN Grade 3.0 (26 cells) or greater





Confirmatory Phase 3 Trial

- Initiation: by end of Q1 2015
- First Patient In (FPI): by end of Q2 2015

1. does not include working capital

POC Phase 2 Trials for Additional Indications: allocated \$1.2 million from proceeds

First Trial: Back-of-eye dose curve trial

- Initiation: Q2 2015
- Top-line data: Q3 2015

- Second Trial: Macular Edema
 - Initiation: Q3 2015
 - Top-line data: Q4 2015



EGP-437 Commercial Strategy



- Clearly-defined and sufficiently concentrated universe of clinicians that treat anterior uveitis in the U.S. which can be addressed by small, focused specialty sales team
- Plan to build key capabilities to support specialty sales team
 - Marketing, market access, sales management and medical affairs
- Opportunity to grow overall market by enabling new point-of-care options
 - Injectable therapies limit administration to experienced ophthalmologist only
 - EGP-437 via EyeGate® II Delivery System can be administered by optometrist, nurse and other staff
- Incremental opportunity through international commercialization
 - Intend to enter into strategic collaboration for commercialization outside the U.S.

Reimbursement

Single-Use Kit

- Includes device and drug
- Combining drug vial and device disposables together:
 - · Ensures use of approved drug with applicator
 - Provides simplification of inventory and invoicing
- Shelf-life established at 24 months (drug and applicator)

Reimbursement: In-office treatment and physician office billing involves multiple code sets.

- CPT Code: In addition to office reimbursement, clinic receives reimbursement for performing treatment
- J-code: The kit (drug + disposables) will be billed under a J-code Payment that would be based on ASP (price we establish) + x% for the kit. EyeGate sells kit to clinic






Strong Patent Portfolio



<section-header><section-header>


* Granted patent protection until 2024, applications if granted extend this to 2029





New IP generated for device and therapeutic - extending market exclusivity period







Capitalization	Shares Outstanding*	% Outstanding*
Common Stock**	5,512,608	78.1%
Stock Options***	1,539,156	21.8%
Warrants	7,247	0.1%
Fully-Diluted Shares Outstanding	7,059,011	100.0%

*As of December 24, 2014 **Common Stock number includes Convertible Notes, Warrants and Preferred Stock that convert upon closing of the IPO ***Outstanding stock options plus stock options available for issuance under equity incentive plans

Investment Highlights



- Late-stage lead asset with clear path to commercialization
 - EGP-437 completed first Phase 3 trial in anterior uveitis, and one pivotal trial left to complete, NDA submission expected by end of year 2016
 - EGP-437 will be developed for additional indications like macular edema a back-of-the-eye disease
- EyeGate[®] II Delivery System a potential paradigm-shift in ophthalmic drug administration
 - Treatment can be performed by range of eye care professionals (injectables must be administered by an experienced ophthalmologist)
 - Long-lasting, professionally delivered treatment eliminates compliance risk of patient-administered drops
- Robust US and international patent portfolio
 - Protection from 2018 through 2029^{*}